

Sogroya[®] (somapacitan-beco) – Expanded indication, new dosage strength

- On April 28, 2023, the <u>FDA approved</u> NovoNordisk's <u>Sogroya (somapacitan-beco)</u>, for the treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH).
 - Sogroya was previously approved for the replacement of endogenous GH in adults with GH deficiency.
- In addition to the expanded indication, the FDA also approved a new dosage strength, 15 mg/1.5 mL (10 mg/mL) in a single-patient-use prefilled pen, of Sogroya.
- The approval of Sogroya for the expanded pediatric indication was based on a randomized, openlabel, active-controlled, parallel-group study conducted in 200 treatment-naïve, pediatric patients with GH deficiency. Patients received weekly Sogroya or daily somatropin. The primary efficacy endpoint was annualized height velocity at week 52.
 - Annualized height velocity was 11.2 cm/year in the Sogroya group vs. 11.7 cm/year in the somatropin group (treatment difference: -0.5; 95% CI: -1.1; 0.2).
- The most common adverse reactions (≥ 5%) with Sogroya use in pediatric patients were nasopharyngitis, headache, pyrexia, pain in extremity, and injection site reaction.
- The recommended dose of Sogroya for the treatment of pediatric patients is 0.16 mg/kg based on actual body weight subcutaneously (SC) once weekly for treatment-naïve patients and patients switching from daily GH (somatropin).
 - Sogroya treatment should be supervised by a healthcare provider who is experienced in the diagnosis and management of pediatric patients with growth failure due to GH deficiency.
 - Dosage should be individualized for each patient based on the growth response.
 - Refer to the Sogroya drug label for further dosing recommendations and for dosing in adults.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.